<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Non-profit</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Pandemic-era nonprofit funding fades from biopharma in 2025</title>
      <description>
        <![CDATA[The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727983</guid>
      <pubDate>Tue, 13 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727983-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Pandemic-era nonprofit funding fades from biopharma in 2025</title>
      <description>
        <![CDATA[The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727764</guid>
      <pubDate>Thu, 08 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727764-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit dealmaking and grants stabilize in a new normal</title>
      <description>
        <![CDATA[Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725899</guid>
      <pubDate>Tue, 04 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725899-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit dealmaking and grants stabilize in a new normal</title>
      <description>
        <![CDATA[Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725777</guid>
      <pubDate>Mon, 03 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725777-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>NIH leads grant funding as awards top $1.1B in 2025</title>
      <description>
        <![CDATA[Nonprofit dealmaking in biopharma has been limited in 2025, with total disclosed value reaching just $99.7 million through July. Nearly all of that came in January, when deals totaled $96.9 million. After a quiet first quarter, modest activity resumed with $1.4 million in April and $1.6 million in July, while the other months saw no reported nonprofit partnerships.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722754</guid>
      <pubDate>Fri, 01 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722754-nih-leads-grant-funding-as-awards-top-11b-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>2024 nonprofit deals plummet from pandemic peak</title>
      <description>
        <![CDATA[Biopharma nonprofit deals remained low in 2024, compared to the pandemic and pre-pandemic years, while grants saw a slight decline from the previous year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716871</guid>
      <pubDate>Fri, 31 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716871-2024-nonprofit-deals-plummet-from-pandemic-peak</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Steady gains in biopharma deals as grants see sharp year-over-year increase</title>
      <description>
        <![CDATA[Through September 2024, biopharma firms secured $720.56 million in nonprofit deals, up in value through July and also marking a 21% rise from the $593.23 million in the first three quarters of 2023, though still falling short of 2019-2022 levels. Grants saw an even sharper surge, jumping 131% year-over-year from $1.66 billion to $3.84 billion in the same period, falling short only of 2020 in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714124</guid>
      <pubDate>Fri, 01 Nov 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/714124-steady-gains-in-biopharma-deals-as-grants-see-sharp-year-over-year-increase</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants reach four-year high of $2.5B; nonprofit deals down</title>
      <description>
        <![CDATA[Through July 2024, biopharma firms received $2.52 billion in grants, marking a 52% increase from $1.66 billion in grants during the same period last year. However, nonprofit deals are at their lowest level on record, according to <em>BioWorld’s </em>records. Although nonprofit deal values were initially higher in April compared to 2023, they have since dropped and are now well below the levels seen in prior years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712163</guid>
      <pubDate>Fri, 30 Aug 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712163-biopharma-grants-reach-four-year-high-of-25b-nonprofit-deals-down</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants see 75% growth YOY, while nonprofit deals decline</title>
      <description>
        <![CDATA[Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703464</guid>
      <pubDate>Tue, 05 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703464-biopharma-grants-see-75-growth-yoy-while-nonprofit-deals-decline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grants see 75% growth YOY, while nonprofit deals decline</title>
      <description>
        <![CDATA[Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703424</guid>
      <pubDate>Fri, 01 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703424-biopharma-grants-see-75-growth-yoy-while-nonprofit-deals-decline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title> Biopharmas receive $1.43B in BARDA grants in 2023</title>
      <description>
        <![CDATA[Biopharma grants are up nearly 150% compared to the same time period last year, largely due to a number of $100 million-plus grants from the Biomedical Advanced Research and Development Authority (BARDA). Meanwhile, nonprofit deal value has declined year-over-year, with the number of transactions down 42.21%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700664</guid>
      <pubDate>Tue, 05 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700664-biopharmas-receive-143b-in-barda-grants-in-2023</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio/nonprofit deals slow as grants pick up in second half of 2022</title>
      <description>
        <![CDATA[As the biopharma industry moves away from the COVID-19 pandemic and expands research in other areas, the amount of money flowing into companies through deals with nonprofit or government entities and grants has plummeted 53% in comparison with 2021. The drop is mainly due to a diminishing number and a lower overall value of bio/nonprofit partnerships. Grants, on the other hand, have risen in both areas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/692802</guid>
      <pubDate>Tue, 27 Dec 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/692802-bio-nonprofit-deals-slow-as-grants-pick-up-in-second-half-of-2022</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio/nonprofit deals slow, grants pick up, in 2022’s second half</title>
      <description>
        <![CDATA[The number of biopharma deals with nonprofit or government entities has dwindled in recent months, while industry grants are climbing. Combined, however, a total of 936 bio/nonprofit deals and grants worth $11.17 billion is down by 37% in comparison with last year’s $17.8 billion and by 58.7% in comparison with 2020’s $27 billion. The volume also is down significantly by 16.8% from 2021 and by 33.4% from 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691625</guid>
      <pubDate>Tue, 15 Nov 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691625-bio-nonprofit-deals-slow-grants-pick-up-in-2022s-second-half</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio-nonprofit deal and grant value of $10.8B down by 22%</title>
      <description>
        <![CDATA[While biopharma grants and company deals with nonprofits and government entities have dropped below each of the last two years, the volume of activity for non-pandemic-related efforts has remained steady. A total of 837 biopharma-nonprofit deals and grants combined so far this year are worth $10.8 billion, which is down by 21.6% over last year’s $13.7 billion and by 15.6% over 2021’s 992 volume. Also down are the deals and grants focused on the COVID-19 pandemic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/690624</guid>
      <pubDate>Fri, 14 Oct 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/690624-bio-nonprofit-deal-and-grant-value-of-108b-down-by-22</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-dollar-down-arrow.webp?t=1638399008" type="image/png" medium="image" fileSize="527882">
        <media:title type="plain">Red arrow down on money background</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma grant and nonprofit deal values plunge</title>
      <description>
        <![CDATA[As the COVID-19 pandemic continues to wind down, the value of biopharma company deals with nonprofit and government entities, as well as grants, are down nearly 64%. Through mid-May 2022, <em>BioWorld</em> has tracked 309 bio/nonprofit deals worth $1.12 billion, and a total of 129 grants valued at $505.85 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519118</guid>
      <pubDate>Tue, 24 May 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519118-biopharma-grant-and-nonprofit-deal-values-plunge</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-coins-and-red-down-arrow.webp?t=1644270925" type="image/png" medium="image" fileSize="195704">
        <media:title type="plain">Gold coins and red down arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>Nonprofit deal and grant activity focused on pandemic falls by 68%</title>
      <description>
        <![CDATA[The number of biopharma deals with nonprofits or government entities has dropped over last year, partly due to fewer COVID-19-related alliances, but the activity in 2022 is still strong in comparison to pre-pandemic years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516078</guid>
      <pubDate>Tue, 15 Feb 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516078-nonprofit-deal-and-grant-activity-focused-on-pandemic-falls-by-68</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Top 10 nonprofit deals all for COVID-19, primarily US government pacts</title>
      <description>
        <![CDATA[Similar to 2020, the COVID-19 pandemic has dominated both biopharma deals with nonprofit entities and grants in 2021. Combined, pandemic deals and grants account for 87% of the total value, but only 22% of the volume, for the year. Through the week of Christmas, <em>BioWorld</em> has recorded 388 grants for the industry, valued at $2.94 billion, and 845 bio/nonprofit deals worth $21.44 billion. Of those, 82 grants worth $1.4 billion and 194 deals worth $19.8 billion involved therapeutic and vaccine development or supply agreements for COVID-19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514677</guid>
      <pubDate>Wed, 29 Dec 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514677-top-10-nonprofit-deals-all-for-covid-19-primarily-us-government-pacts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Women-handshake-with-virology-graphics.webp?t=1640805941" type="image/png" medium="image" fileSize="459084">
        <media:title type="plain">Women handshake with virology graphics</media:title>
      </media:content>
    </item>
    <item>
      <title>COVID-19 still accounts for bulk of nonprofit deals and grants</title>
      <description>
        <![CDATA[On target with last year, a total of 87% of funds recorded in 2021 through biopharma collaborations with nonprofit entities by the end of October are focused on COVID-19 pandemic efforts. The pandemic accounts for 54% of the money collected through grants, which is still a sturdy amount but down from 76% in 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512888</guid>
      <pubDate>Fri, 29 Oct 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512888-covid-19-still-accounts-for-bulk-of-nonprofit-deals-and-grants</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/coronavirus-money.webp?t=1745260839" type="image/jpeg" medium="image" fileSize="343733">
        <media:title type="plain">Coronavirus and coins </media:title>
      </media:content>
    </item>
    <item>
      <title>Slipping behind last year, nonprofit deals and grants still driven by COVID-19</title>
      <description>
        <![CDATA[Biopharma company deals with nonprofit entities, as well as grants, are not keeping the same pace as last year, but the proportion of money flowing into COVID-19 efforts continues to account for the majority of those recorded overall.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510762</guid>
      <pubDate>Tue, 24 Aug 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510762-slipping-behind-last-year-nonprofit-deals-and-grants-still-driven-by-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Pandemic efforts dominate with 76% of the nonprofit deal and grant value</title>
      <description>
        <![CDATA[Although more than a third of U.S. citizens are fully vaccinated from COVID-19 and society moves closer to normalcy in many parts of the world, the SARS-CoV-2 virus continues to dramatically impact biopharma dealmaking with nonprofit entities, as well as grant awards.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507274</guid>
      <pubDate>Wed, 19 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507274-pandemic-efforts-dominate-with-76-of-the-nonprofit-deal-and-grant-value</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Accumulus’ collaborators plan to streamline data sharing and communications</title>
      <description>
        <![CDATA[Busting a logjam of inadequate data sharing methods and communications between pharmas and health authorities around the world is the impetus behind the creation of nonprofit Accumulus Synergy Inc., whose common, cloud-based platform is designed to make the regulatory process easier for everyone involved. The coalition’s initial membership is a Who’s Who of big pharma: Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Glaxosmithkline plc, the Janssen Pharmaceutical Cos. of Johnson & Johnson, Eli Lilly and Co., Pfizer Inc., Roche Holding AG, Sanofi SA and Takeda Pharmaceutical Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/502727</guid>
      <pubDate>Fri, 22 Jan 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/502727-accumulus-collaborators-plan-to-streamline-data-sharing-and-communications</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Cloud-data-sharing-illustration.webp?t=1611348855" type="image/png" medium="image" fileSize="526106">
        <media:title type="plain">Cloud data sharing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>U.S. government responsible for 68% of biopharma’s nonprofit and grant funding in 2020</title>
      <description>
        <![CDATA[The amount of money flowing into the biopharma industry via grants and collaborations with nonprofit and government entities is a 272% increase over last year, with efforts to fight the COVID-19 pandemic accounting for 84% of the total for 2020.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501858</guid>
      <pubDate>Tue, 29 Dec 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501858-us-government-responsible-for-68-of-biopharmas-nonprofit-and-grant-funding-in-2020</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-budget-spending-money.webp?t=1588689236" type="image/png" medium="image" fileSize="1809708">
        <media:title type="plain">U.S. flag and money</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma nonprofit/grant deals triple that of 2019</title>
      <description>
        <![CDATA[The combined total of biopharma nonprofit collaborations and grants in 2020 has reached about $24 billion, more than three times the amount recorded for 2019.]]>
      </description>
      <guid>http://www.bioworld.com/articles/500642</guid>
      <pubDate>Wed, 25 Nov 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/500642-biopharma-nonprofitgrant-deals-triple-that-of-2019</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Pandemic accounts for 86% of nonprofit deals and grants in 2020</title>
      <description>
        <![CDATA[Without the COVID-19 pandemic, projected values of biopharma nonprofit collaborations and grants would be 72% and 30% below last year’s levels, although it is impossible to know what deals may have come to fruition in a world absent of the disruptive SARS-CoV-2 virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/498215</guid>
      <pubDate>Fri, 25 Sep 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/498215-pandemic-accounts-for-86-of-nonprofit-deals-and-grants-in-2020</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Nonprofit-stamp.webp?t=1601056571" type="image/png" medium="image" fileSize="189698">
        <media:title type="plain">Nonprofit stamp</media:title>
      </media:content>
    </item>
  </channel>
</rss>
